StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) income statement

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)

Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –

Neurocrine Biosciences Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
98.0%
Operating margin
23.6%
Net margin
20.9%
Return on equity, FY2025
16.4%

Financial strength

Current ratio
1.87
Debt to equity
–
Debt to assets
–
Cash to current liabilities
38.0%

Valuation

P/E ratio
23.9
Price to sales
4.91
Price to book
4.48
Dividend yield
–

See a number that looks wrong?